Clinical trial
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
NCT03236675 is registered in ClinicalTrials.gov with Exosome Diagnostics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
- Lead sponsor
- Exosome Diagnostics, Inc.
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- March 31, 2015
- Completion date
- February 28, 2022
- Enrollment
- 60 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.